Articles

In this subanalysis of the AG221-C-001 phase 1 study, enasidenib monotherapy was found to be well-tolerated, and yielded hematologic responses in previously untreated older patients with IDH2-mutated (mIDH2) acute myeloid leukemia (AML) who are not fit to receive standard cytotoxic chemotherapy.

The initial results of a phase 1 study suggest that combination therapy with ivosidenib or enasidenib plus standard induction chemotherapy is well-tolerated and effective in newly diagnosed patients with IDH-mutated (mIDH), relapsed/refractory acute myeloid leukemia (AML).

In this analysis, the hedgehog pathway inhibitor sonidegib plus azacitidine combination therapy showed encouraging antileukemia activity in terms of high rate of disease stabilization, particularly in the relapsed/refractory acute myeloid leukemia patient population.

The results of the Radius-X expanded treatment protocol showed a safety profile that was consistent with that previously described in patients with FLT3 mutation–positive, newly diagnosed acute myeloid leukemia (AML).

Ivosidenib monotherapy is well-tolerated and produced durable remissions in high-risk patients with relapsed/refractory acute myeloid leukemia (AML).

Interim results of an ongoing phase 1 study showed that the addition of the selective FLT3 inhibitor quizartinib to azacitidine or low-dose cytarabine produced high overall response rates in patients with FLT3-ITD–mutated myeloid leukemias.

The preliminary results of a multicenter phase 1b dose-escalation study evaluated the safety, tolerability, and efficacy of 2 novel venetoclax-based combination therapies, in combination with the MEK inhibitor cobimetinib or the MDM2 inhibitor idasanutlin, in relapsed/refractory (R/R) acute myeloid leukemia (AML).

Chicago, IL—Maintenance therapy can improve overall survival (OS) in older and younger patients with mantle-cell lymphoma (MCL), based on current experience with rituximab (Rituxan) therapy, but the optimal dose and dosing schedule remain under investigation.

Chicago, IL—The global International Duration Evaluation of Adjuvant Chemotherapy (IDEA) study suggests that some patients with surgically resected stage III colon cancer can safely and effectively receive only 3 months of chemotherapy instead of the standard 6 months. The data were particularly convincing for patients with low-risk, surgically resected stage III colon cancer. These data set a new standard for the treatment of patients with stage III colon cancer, according to expert opinion presented at the 2017 ASCO annual meeting.

Chicago, IL—The addition of the investigational CDK4/CDK6 inhibitor abemaciclib to fulvestrant (Faslodex) extended progression-free survival (PFS) by 7 months in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, reported George W. Sledge, Jr, MD, Professor, Medical Oncology, Stanford University Medical Center, Palo Alto, CA, who presented the results of a large study at the 2017 ASCO annual meeting.